Influence of Food Matrix on Prebiotic Efficacy in Inulin Type Fructans

NCT ID: NCT05581615

Last Updated: 2022-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-20

Study Completion Date

2021-10-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to investigate whether the food matrix has an influence on the prebiotic efficacy (bifidobacteria growth) of chicory-derived Orafti® inulin in healthy adult volunteers. The main question it aims to answer is:

Does the food matrix influence the prebiotic effect of chicory-derived inulin in terms of stimulation of bifidobacteria in the gut microbiota Participants will receive one of three food items containing inulin or pure inulin dissolved in water daily for 10 days. The food items or pure inulin powder will deliver 10 g/d inulin split into two dosages of 5 g/d. They will provide stool samples before and at the end of the intake period. They will record any gastrointestinal sensations and bowel habits in a diary. Urinary samples will be collected at baseline and end of intervention for analysis of metabolites with Nuclear Magnetic resonance (NMR).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

gut microbiota, prebiotic intake, Bifidobacterium

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pure inulin

2 x 5 g/d inulin

Group Type ACTIVE_COMPARATOR

Inulin

Intervention Type OTHER

Each intervention provided 10 g/d inulin split into two dosages of 5 g.

Shortbread containing inulin

2 x per day shortbread containing 5 g inulin per serving

Group Type EXPERIMENTAL

Inulin

Intervention Type OTHER

Each intervention provided 10 g/d inulin split into two dosages of 5 g.

Rice drink containing inulin

2 x per day rice drink containing 5 g inulin per serving

Group Type EXPERIMENTAL

Inulin

Intervention Type OTHER

Each intervention provided 10 g/d inulin split into two dosages of 5 g.

Milk chocolate containing inulin

2 x per day milk chocolate containing 5 g inulin per serving

Group Type EXPERIMENTAL

Inulin

Intervention Type OTHER

Each intervention provided 10 g/d inulin split into two dosages of 5 g.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inulin

Each intervention provided 10 g/d inulin split into two dosages of 5 g.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Volunteer is healthy at the time of pre-examination
* Volunteer is aged ≥ 18 to ≤ 65 years at the time of pre-examination
* Volunteer's BMI is ≥ 18,5 and ≤ 29,9
* Volunteer follows an average Western European diet
* Volunteer has a stool frequency of at least 3 bowel movements per week
* Volunteer is able and willing to comply with the study instructions
* Volunteer is suitable for participation in the study according to the investigator/study personnel
* Written informed consent is given by volunteer

Exclusion Criteria

* No command of any local language
* Gastrointestinal disorders including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) or other conditions that might affect the gut environment
* Food allergies or intolerances
* Vegetarians, vegans and/or extreme diets including high protein/fibre, ketogenic, intermittent fasting and/or carnivore
* Using drugs (e.g. antibiotics, aspirin, proton pump inhibitors) influencing gastrointestinal function (8 weeks before intervention)
* Use of laxatives and labelled pre- and probiotics in the previous 4 weeks before the beginning of intervention
* Clinically significant diabetes
* Volunteers currently involved or will be involved in another clinical or food study
* History of drug (pharmaceutical or recreational) or alcohol abuse.
* Has received bowel preparation for investigative procedures in the 4 weeks prior to the study
* Has undergone surgical resection of any part of the bowel.
* If participants are pregnant or are lactating
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Reading

OTHER

Sponsor Role collaborator

Beneo-Institute

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert A Rastall, Prof

Role: PRINCIPAL_INVESTIGATOR

University of Reading

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Reading

Reading, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY Number - 36/2020

Identifier Type: -

Identifier Source: org_study_id